Sagitta Asset Management has designed a global healthcare fund that aims to exploit investment opportunities in this small but rapidly expanding sector.
This Dublin based Ucits invests in healthcare stocks such as biotechnology, medical technology and healthcare management. Stocks will be selected according to their growth potential, although the biotechnology stocks will be later stage companies rather than those in the early stages of development.
The world's population is ageing as people are living longer and technology is helping to make medical breakthroughs possible, particularly in the US. There is also an increased demand for drugs and treatments. Figures from the Department of Health shows the number of prescriptions issued in the UK rose by 3.2 per cent between 1998 and 1999.
This healthcare fund is a specialist fund that may be suitable for high net worth clients who are excited by the prospect of scientific advances and who are prepared to withstand the risk of high volatility.
According to Standard & Poor's the Sagitta focused global growth fund is ranked 44 out of 297 funds based on £1,000 invested on a bid to bid to basis with gross income reinvested over three years to February 26, 2001